Literature DB >> 18160291

Sporadic inclusion body myositis: a continuing puzzle.

M Needham1, F L Mastaglia.   

Abstract

There is now compelling evidence that sporadic inclusion body myositis (sIBM) is a muscle-specific autoimmune disease in which both T and B-cells play a part and in which both cytotoxic muscle fibre necrosis and degeneration occur. However the factors responsible for breakdown of immune tolerance and the nature of the target antigens expressed by muscle fibres remain unknown. Genetic factors are known to contribute to susceptibility, in particular MHC haplotyes which may influence antigenic presentation, and could also operate through genetic variations in muscle fibre constituents or immune effector mechanisms. Viral infection may act as a trigger mechanism, as in cases of HIV-associated sIBM. Our understanding of the mechanisms leading to the degenerative changes in muscle fibres is still incomplete. Protein misfolding and proteasomal dysfunction rather than defective transcriptional control is likely to underlie the abnormal accumulation of multiple proteins in the muscle fibre inclusions. However, aberrant transcription is thought to be the basis for the accumulation of potentially toxic mutant protein forms (e.g. UBB(+1)). The origin of the multiple clonally expanded somatic mtDNA mutations in COX-negative segments of muscle fibres remains uncertain but may be linked to the effects of oxidative stress. It is proposed that the disproportionate involvement of certain muscles in sIBM may be due to the existence of muscle group-specific transcriptomes which are differentially affected by the disease process and that the male predominance of the disease may indicate the influence of genes preferentially expressed in males. There is a need to develop better animal models of sIBM in which the relationship between the inflammatory and degenerative components of the disease as well as the gender difference in susceptibility and differential vulnerability of different muscle groups can be more critically investigated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160291     DOI: 10.1016/j.nmd.2007.11.001

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  14 in total

1.  ANT1 is reduced in sporadic inclusion body myositis.

Authors:  E Barca; M Aguennouz; A Mazzeo; S Messina; A Toscano; G L Vita; S Portaro; D Parisi; C Rodolico
Journal:  Neurol Sci       Date:  2012-02-21       Impact factor: 3.307

2.  Sporadic inclusion body myositis: new insights and potential therapy.

Authors:  Pedro M Machado; Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Opin Neurol       Date:  2014-10       Impact factor: 5.710

3.  Comparison of Serum rAAV Serotype-Specific Antibodies in Patients with Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Inclusion Body Myositis, or GNE Myopathy.

Authors:  Deborah A Zygmunt; Kelly E Crowe; Kevin M Flanigan; Paul T Martin
Journal:  Hum Gene Ther       Date:  2016-12-29       Impact factor: 5.695

4.  Primary over-expression of AβPP in muscle does not lead to the development of inclusion body myositis in a new lineage of the MCK-AβPP transgenic mouse.

Authors:  Yue-Bei Luo; Russell D Johnsen; Lisa Griffiths; Merrilee Needham; Victoria A Fabian; Sue Fletcher; Steve D Wilton; Frank L Mastaglia
Journal:  Int J Exp Pathol       Date:  2013-10-31       Impact factor: 1.925

Review 5.  Immunotherapy of myositis: issues, concerns and future prospects.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Rheumatol       Date:  2010-02-02       Impact factor: 20.543

Review 6.  Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHC.

Authors:  F L Mastaglia
Journal:  Acta Myol       Date:  2009-10

7.  N-terminal α Dystroglycan (αDG-N): A Potential Serum Biomarker for Duchenne Muscular Dystrophy.

Authors:  Kelly E Crowe; Guohong Shao; Kevin M Flanigan; Paul T Martin
Journal:  J Neuromuscul Dis       Date:  2016-05-27

8.  FOXO/4E-BP signaling in Drosophila muscles regulates organism-wide proteostasis during aging.

Authors:  Fabio Demontis; Norbert Perrimon
Journal:  Cell       Date:  2010-11-24       Impact factor: 41.582

Review 9.  Inclusion body myositis: review of recent literature.

Authors:  Steven A Greenberg
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081

10.  Vacuolar myopathy in a dog resembling human sporadic inclusion body myositis.

Authors:  Jason King; Richard A LeCouteur; Monica Aleman; D Colette Williams; Peter F Moore; Ling T Guo; Andrew P Mizisin; G Diane Shelton
Journal:  Acta Neuropathol       Date:  2009-08-29       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.